C-Biomex announced on Thursday that it's joining forces with MD Anderson Cancer Center for a significant project focusing on radiopharmaceuticals aimed at treating kidney cancer. This collaboration marks a pivotal step forward in the development of CBT-001, a therapy designed to target CA-9 (Carbonic anhydrase 9), a protein found to be overexpressed in kidney, breast, and lung cancers. The therapy involves incorporating a radioisotope (Lutecium-177) into C-Biomex's own ligand, making it a promising candidate for combating these types of cancer.
The entire clinical trial process for CBT-001 will be conducted at MD Anderson Cancer Center to meet the strict requirements set by the FDA for investigational new drug (IND) applications in the United States. Dr. Charles Manning, a distinguished professor at MD Anderson and the current president of the World Molecular Imaging Society (WMIS), will lead the research as the principal investigator.
C-Biomex's CEO, Cha Jun-hoe, expressed confidence in the partnership, highlighting MD Anderson and Professor Manning's expertise in therapeutic radiopharmaceutical development. "We are excited to work with MD Anderson and Professor Manning, who are ideal partners to complement our capabilities in all phases of therapeutic radiopharmaceutical development," said Cha Jun-hoe. He also emphasized their commitment to swiftly advancing trials for FDA IND approval and expressed openness to exploring additional targets for collaboration.
Therapeutic radiopharmaceuticals, like CBT-001, represent a groundbreaking approach in cancer treatment. Similar to antibody drug conjugates (ADCs), these drugs specifically target cancer cells, delivering radioisotopes instead of toxins. Leveraging its proprietary peptide discovery platform technology, CUSTM, C-Biomex is not only developing CBT-001 but also working on other next-generation therapeutic radiopharmaceuticals with promising properties.
Overall, this collaboration between C-Biomex and MD Anderson holds great promise for advancing cancer treatment and bringing hope to patients battling kidney cancer and other related conditions.
md anderson